Atara tab-cel
WebOct 4, 2024 · SOUTH SAN FRANCISCO, Calif. & CASTRES, France -- October 4, 2024 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced an … WebIn 2024, Atara and Pierre Fabre entered a strategic collaboration to commercialize tabelecleucel (tab-cel ® )* in Europe, Middle East, Africa, and other select emerging markets for Epstein-Barr virus (EBV) positive cancers. Atara retained full rights to tab-cel ® in other major markets, including North America, Asia Pacific, and Latin America.
Atara tab-cel
Did you know?
WebDec 14, 2024 · Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post ... WebNov 30, 2024 · Atara will present findings from the ALLELE study and additional tab-cel data in eight abstracts at the 63 rd American Society of Hematology (ASH) Annual Meeting taking place December 11-14, 2024 ...
WebOct 14, 2024 · Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post ... WebJun 4, 2024 · SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its …
WebDec 19, 2024 · Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein … WebAug 17, 2024 · If Atara Biotherapeutics can gain European approval or U.S. FDA approval of tab-cel for this specific indication, it would be huge. As I noted above, there is an …
WebDec 17, 2024 · Atara's lead indication is rituximab refractory patients with Epstein Barr Virus associated post-transplant lymphoproliferative diseases, or EBV+PTLD. Lead asset is tabelecleucel (tab-cel), an ...
WebJan 10, 2024 · Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential ... cheesecake cutter for small piecesWebMar 31, 2024 · Atara’s pipeline includes tab-cel ® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell … flcc choirWebDec 14, 2024 · Tabelecleucel (tab‐cel) is an off-the-shelf, allogeneic T-cell immunotherapy in development for the treatment of Epstein-Barr virus-positive post-transplant … flccc frontlineWebDec 20, 2024 · Our investigational T-cell therapies target difficult-to-treat Epstein-Barr virus (EBV)-driven conditions, including certain cancers and multiple sclerosis, as well as a … flccc i-mask+protocol early treatmentWebAug 8, 2024 · Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel ® (tabelecleucel) in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD); ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment … cheesecake cypress txWebJan 9, 2024 · Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative … cheesecakecwith cooks essentialWebMay 30, 2024 · Atara Biotherapeutics’s investigative therapy Tab-cel (tabelecleucel) is a potentially safe and viable option to treat transplant-derived lymphoma, according to long-term data from two Phase 2 clinical trials.. The new results will be presented in a poster titled, “ Long Term Outcomes of Tabelecleucel (Allogeneic Third-Party EBV-Targeted … flccc home